Brought to you by 
Bristol pays up to $520mm for immuno-oncology company Cormorant
08 Sep 2020
Executive Summary
Bristol-Myers Squibb Co. acquired Cormorant Pharmaceuticals AB, a private immuno-oncology company founded in 2010, for $95mm in up-front and near-term milestones, plus up to $425mm in development and regulatory earn-outs.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bristol pays up to $520mm for immuno-oncology company Cormorant
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice